The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
5 Institutions
Seoul, South Korea
Percent change from baseline to 12 week in visceral fat area measured by CT
Time frame: baseline and 12 week
improvement of metabolic profile
Time frame: baseline and 12 week
change of insulin resistance
Time frame: baseline and 12 week
change of BMI
Time frame: baseline and 12 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.